期刊文献+

流式细胞术检测微小残留病预测儿童急性B淋巴细胞白血病复发的意义 被引量:12

Detection of minimal residual disease by flow cytometry as a useful approach for predicting relapse in childhood B-lingeage acute lymphoblastic leukemia
原文传递
导出
摘要 目的:探讨流式细胞术在儿童急性B淋巴细胞白血病(B-lineage acute lymphoblastic leukemia,B-ALL)患者化疗全程检测微小残留病(minimal residual disease,MRD),观察其在预测复发中的意义。方法:采用四色多参数流式细胞术对我中心291例B-ALL患儿在化疗第19天、第35天、第55天(中高危组)、第14~17周、第28~36周、第52~54周、第78~83周、第102~107周、停药及停药后分别进行MRD检测。结果:①291例患儿中MRD<0.01%、0.01%~0.1%、0.1%~1%和>1%分别有169例、35例、44例和43例,其7年累计复发率分别为4.1%、17.1%、29.5%和62.8%。4组复发率差异有统计学意义(P﹤0.0001)。②各时间点MRD阳性组复发率均高于MRD阴性组,差异均有统计学意义(第19天,P=0.0021;第55天,P=0.0008;停药后,P=0.0025,余P均<0.0001)。③第35天MRD阳性在早期复发和晚期复发患儿中均常见;14~17周MRD阳性对预测早期复发意义较大;停药后MRD阳性对预测晚期复发意义较大。结论:采用流式细胞术检测MRD阳性情况在一定程度上可预测白血病复发。各时间点MRD阳性与复发均有一定相关性,且预测复发的意义不同。 Objective To study the value of detection of minimal residual disease(MRD) by flow cytometry(FCM) during the process of chemotherapy for predicting relapse in childhood B-lingeage acute lymphoblastic leukemia.Methods MRD was detected by four-color flow cytometry on day 19,day 35,day 55(only for medium-or high-risk group) and week 13-17,week 28-36,week 52-54,week 78-83,week 102-107,last day of the chemotherapy process and during follow-up in 291 childhood B-lingeage acute lymphoblastic leukemia patients.Results ① MRD were 〈0.01%,0.01%-0.1%,0.1%-1%and 〉1% in 169,35,44,43 patients,respectively.The 7 years cumulative incidence of relapse were 4.1%,17.1%,29.5% and 62.8% in patients with MRD〈0.01%,0.01%-0.1%,0.1%-1%and 〉1%,respectively.The differences between these four groups were statistically significant(P〈0.0001).② The difference in relapse rate was statistically significant between MRD positive and MRD negative patients at every detection time point.(P=0.0021 on day 19,P=0.0008 on day 55,P=0.0025 during follow-up,and other time points P〈0.0001) ③ Day 35 was an important time point to predict early and late relapse,week 14-17 was an important time point to predict early relapse,and MRD positive during follow-up was valuable for predicting late relapse.Conclusions MRD detection by flow cytometry is valuable for predicting relapse of childhood B-ALL and has different significance at different time points.
出处 《诊断学理论与实践》 2012年第2期141-144,共4页 Journal of Diagnostics Concepts & Practice
关键词 急性B淋巴细胞白血病 微小残留病 流式细胞术 复发 儿童 B-lineage acute lymphoblastic leukemia; Minimal residual disease; Flow cytomety; Relapse; Children
  • 相关文献

参考文献18

  • 1Mullighan CG,Phillips LA,Su X. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia[J].Science,2008,(5906):1377-1380.doi:10.1126/science.1164266.
  • 2Campana D. Status of minimal residual disease testing in childhood haematological malignancies[J].British Journal of Haematology,2008,(04):481-489.
  • 3Campana D,Pui CH. Detection of minimal residual disease in acute leukemia:methodologic advances and clinical significance[J].Blood,1995,(06):1416-1434.doi:10.1109/TEVC.2010.2052054.
  • 4Campana D,Coustan-Smith E. Minimal residual disease studies by flow cytometry in acute leukemia[J].Acta Haematologica,2004,(1-2):8-15.doi:10.1159/000077554.
  • 5汤静燕,顾龙君,薛惠良,陈静,潘慈,吴文婷,沈树红,董璐,周敏,叶启东,江华.ALL-2005方案治疗158例儿童急性淋巴细胞白血病诱导缓解期疗效评价及中期随访报告[J].中华血液学杂志,2009,30(5):289-293. 被引量:30
  • 6Campana D. Minimal residual disease in acute lymphoblastic leukemia[J].Hematology(American Society Hematology Education Program),2010.7-12.
  • 7Campana D,Coustan-Smith E. Detection of minimal residual disease in acute leukemia by flow cytometry[J].Cytometry,1999,(04):139-152.doi:10.1002/(SICI)1097-0320(19990815)38:4<139::AID-CYTO1>3.0.CO;2-H.
  • 8Coustan-Smith E,Campana D. Immunologic minimal residual disease detection in acute lymphoblastic leukemia:A comparative approach to molecular testing[J].Best Practice and Research:Clinical Rheumatology,2010,(03):347-358.
  • 9Campana D. Progress of minimal residual disease studies in childhood acute leukemia[J].Curr Hematol Malig Rep,2010,(03):169-176.
  • 10Stow P,Key L,Chen X. Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia[J].Blood,2010,(23):4657-4663.doi:10.1182/blood-2009-11-253435.

二级参考文献51

  • 1刘艳荣,王卉,常艳,程翼飞,付家瑜,张乐萍,刘桂兰,陈珊珊.四色流式细胞术检测急性B淋巴细胞白血病残留细胞[J].中华血液学杂志,2005,26(6):327-331. 被引量:13
  • 2汤静燕,薛惠良,顾龙君,陈静,潘慈,陈静,王耀平,叶辉,董璐,邹佳音.儿童急性淋巴细胞性白血病治疗依从失败及治疗失败分析[J].中华儿科杂志,2005,43(7):490-493. 被引量:22
  • 3潘慈,顾龙君,薛惠良,陈静,董璐,周敏,罗长樱,王耀平,汤静燕.儿童急性淋巴细胞性白血病诱导化疗修正方案的近期临床评估[J].中华儿科杂志,2007,45(5):324-328. 被引量:12
  • 4Vora A, Mitchell CD, Lennard L,et al. Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia : a randomised trial. Lancet,2006,368 : 1339-1348.
  • 5Moghrabi A, Levy DE, Asselin B, et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood,2007,109:896-904.
  • 6Pui C H, Sandlund JT, Pei D,et al. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study ⅩⅢB at St Jude Children' s Research Hospital. Blood,2004,104 : 2690-2696.
  • 7Arico M, Valsecchi MG, Conter V, et al. Improved outcome in high-risk childhood acute lymphoblastic leukemia defined by prednisone-poor response treated with double Bedin-Frankfurt-Muenster protocol Ⅱ. Blood, 2002,100:420-426.
  • 8Schrappe M, Reiter A, Ludwig WD,et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood,2000, 95:3310-3322.
  • 9Zhou J, Goldwasser MA, Li A,et al. Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01. Blood ,2007,110 : 1607-1611.
  • 10Raft T, G~kbuget N, Ltischen S, et al. Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment : data from the GMALL 06/99 and 07/03 trials. Blood,2007,109:910-915.

共引文献76

同被引文献86

  • 1朱勇梅,陈赛娟.微小残留病检测方法及其临床应用[J].中国实验血液学杂志,2005,13(6):1131-1136. 被引量:13
  • 2Dworzak MN,Gaipa G,Schumich A,et aLModulation of anti- gen expression in B-cell precursor acute lymphoblastic leukemia during induction therapy is partly transient: evi- dence for a drug-induced regulatory phenomenon.Results of the AIEOP-BFM-ALL-FLOW-MRI)-Study Group[J]. Cytometry B Clin Cytom, 201 O, 78 (3) : 147-153.
  • 3Coustan-Smith E, Campana D.Immunologic minimal resid- ual disease detection in acute lymphoblastic leukemia: a com- parative approach to molecular testing [J]. Best Pract Res Clin Haematol, 2010,23 (3) : 347-358.
  • 4Cui L,Li Z,Wu M,et al.Combined analysis of minimal residual disease at two time points and its value for risk stratification in childhood B-lineage acute lymphoblastic leukemia[J].Leuk Res ,2010,34(10) : 1314-1319.
  • 5AL-MAWALI A, GILLISS D, LEWIS 1, et al. The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia [J]. Am J Clin Pathol, 2009, 131(1) : 16-26,.
  • 6ARBER DA, BRUNNING RD, LE BEAU MM, et al. Acute myeloid leukemia and related precursor neoplasms. In: WHO classification of tumours of the haematopoietic and lymphoid tissues [ M ]. 4th ed. Lyon: International Agency for Research on Cancer, 2008 : 109-147.
  • 7MAURILLO L, BUCCISANO F, SPAGNOLI A, et al. Monitoring of minimal residual disease in adultacute myeloid leukemia using peripheral blood as an alternative source to bone marrow[ J]. Haematologic, 2007, 92(5): 605-611.
  • 8BUCCISANO F, MAURILLO L, DEL PR1NCIPE MI, et al. Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia [J]. Blood, 2012, 119(2):332-341.
  • 9COUSTAN-SMITH E, SANCHO J, HANCOCK ML, et al. Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia [ J ]. Blood, 2002, 100 (7) : 2399-2402.
  • 10BUCCISANO F, MAURILLO L, SPAGNOLI A, et al. Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia [ J ]. Blood, 2010,116 ( 13 ) :2295-2303.

引证文献12

二级引证文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部